PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 31408840-0 2019 Protective effects of Clematichinenoside AR against inflammation and cytotoxicity induced by human tumor necrosis factor-alpha. clematichinenoside 22-40 tumor necrosis factor Homo sapiens 99-126 31785117-0 2020 Clematichinenoside protects renal tubular epithelial cells from hypoxia/reoxygenation injury in vitro through activating the Nrf2/HO-1 signaling pathway. clematichinenoside 0-18 NFE2 like bZIP transcription factor 2 Homo sapiens 125-129 31395423-0 2019 Clematichinenoside Facilitates Recovery of Neurological and Motor Function in Rats after Cerebral Ischemic Injury through Inhibiting Notch/NF-kappaB Pathway. clematichinenoside 0-18 notch receptor 1 Homo sapiens 133-138 31395423-0 2019 Clematichinenoside Facilitates Recovery of Neurological and Motor Function in Rats after Cerebral Ischemic Injury through Inhibiting Notch/NF-kappaB Pathway. clematichinenoside 0-18 nuclear factor kappa B subunit 1 Homo sapiens 139-148 31395423-1 2019 PURPOSE: The present study was to observe the therapeutic efficiency of Clematichinenoside (AR) on cerebral ischemic injury in rats, especially on neurological and motor function recovery and to explore the underlying mechanism. clematichinenoside 72-90 ferredoxin reductase Rattus norvegicus 92-94 31408840-3 2019 Therefore, we aimed to explore the protective effects of Clematichinenoside AR against inflammation and cytotoxicity induced by human TNF-alpha. clematichinenoside 57-75 tumor necrosis factor Homo sapiens 134-143 28003810-0 2016 Succinate/NLRP3 Inflammasome Induces Synovial Fibroblast Activation: Therapeutical Effects of Clematichinenoside AR on Arthritis. clematichinenoside 94-112 NLR family, pyrin domain containing 3 Rattus norvegicus 10-15 26793066-0 2015 Clematichinenoside Serves as a Neuroprotective Agent Against Ischemic Stroke: The Synergistic Action of ERK1/2 and cPKC Pathways. clematichinenoside 0-18 mitogen activated protein kinase 3 Rattus norvegicus 104-110 23852993-1 2013 Clematichinenoside AR (C-AR), a pentacyclic triterpenoid saponin with anti-inflammatory and anti-rheumatoid activities, is the main active component of the traditional Chinese medicine Clematidis Radix et Rhizoma. clematichinenoside 0-18 CXADR, Ig-like cell adhesion molecule Rattus norvegicus 19-27 25979856-0 2015 An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-alpha mediated apolipoprotein A-I, A-II and C-III. clematichinenoside 79-97 peroxisome proliferator activated receptor alpha Homo sapiens 117-165 25979856-0 2015 An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-alpha mediated apolipoprotein A-I, A-II and C-III. clematichinenoside 79-97 apolipoprotein A1 Homo sapiens 175-193 25979856-0 2015 An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-alpha mediated apolipoprotein A-I, A-II and C-III. clematichinenoside 79-97 NLR family pyrin domain containing 3 Homo sapiens 195-209 25979856-2 2015 The aim of the study was to scrutinize the effect of Clematichinenoside (AR) on dyslipidemia-induced atherosclerosis and explore its capability on expression of Peroxisome proliferator-activated receptor-alpha (PPAR-alpha), apolipoprotein A-I (APOA1) and A-II (APOA2), and suppression of apolipoprotein C-III (APOC3) genes and proteins. clematichinenoside 53-71 peroxisome proliferator activated receptor alpha Homo sapiens 161-209 25979856-2 2015 The aim of the study was to scrutinize the effect of Clematichinenoside (AR) on dyslipidemia-induced atherosclerosis and explore its capability on expression of Peroxisome proliferator-activated receptor-alpha (PPAR-alpha), apolipoprotein A-I (APOA1) and A-II (APOA2), and suppression of apolipoprotein C-III (APOC3) genes and proteins. clematichinenoside 53-71 peroxisome proliferator activated receptor alpha Homo sapiens 211-221 25979856-2 2015 The aim of the study was to scrutinize the effect of Clematichinenoside (AR) on dyslipidemia-induced atherosclerosis and explore its capability on expression of Peroxisome proliferator-activated receptor-alpha (PPAR-alpha), apolipoprotein A-I (APOA1) and A-II (APOA2), and suppression of apolipoprotein C-III (APOC3) genes and proteins. clematichinenoside 53-71 apolipoprotein A1 Homo sapiens 224-242 25979856-2 2015 The aim of the study was to scrutinize the effect of Clematichinenoside (AR) on dyslipidemia-induced atherosclerosis and explore its capability on expression of Peroxisome proliferator-activated receptor-alpha (PPAR-alpha), apolipoprotein A-I (APOA1) and A-II (APOA2), and suppression of apolipoprotein C-III (APOC3) genes and proteins. clematichinenoside 53-71 apolipoprotein A1 Homo sapiens 244-249 25979856-2 2015 The aim of the study was to scrutinize the effect of Clematichinenoside (AR) on dyslipidemia-induced atherosclerosis and explore its capability on expression of Peroxisome proliferator-activated receptor-alpha (PPAR-alpha), apolipoprotein A-I (APOA1) and A-II (APOA2), and suppression of apolipoprotein C-III (APOC3) genes and proteins. clematichinenoside 53-71 NLR family pyrin domain containing 3 Homo sapiens 255-259 25979856-2 2015 The aim of the study was to scrutinize the effect of Clematichinenoside (AR) on dyslipidemia-induced atherosclerosis and explore its capability on expression of Peroxisome proliferator-activated receptor-alpha (PPAR-alpha), apolipoprotein A-I (APOA1) and A-II (APOA2), and suppression of apolipoprotein C-III (APOC3) genes and proteins. clematichinenoside 53-71 apolipoprotein A2 Homo sapiens 261-266 25979856-2 2015 The aim of the study was to scrutinize the effect of Clematichinenoside (AR) on dyslipidemia-induced atherosclerosis and explore its capability on expression of Peroxisome proliferator-activated receptor-alpha (PPAR-alpha), apolipoprotein A-I (APOA1) and A-II (APOA2), and suppression of apolipoprotein C-III (APOC3) genes and proteins. clematichinenoside 53-71 apolipoprotein C3 Homo sapiens 288-308 25979856-2 2015 The aim of the study was to scrutinize the effect of Clematichinenoside (AR) on dyslipidemia-induced atherosclerosis and explore its capability on expression of Peroxisome proliferator-activated receptor-alpha (PPAR-alpha), apolipoprotein A-I (APOA1) and A-II (APOA2), and suppression of apolipoprotein C-III (APOC3) genes and proteins. clematichinenoside 53-71 apolipoprotein C3 Homo sapiens 310-315 25463279-0 2015 Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-alpha-treated endothelial cells via NADPH oxidase-dependent IkappaB kinase/NF-kappaB pathway. clematichinenoside 0-18 vascular cell adhesion molecule 1 Homo sapiens 28-34 25463279-0 2015 Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-alpha-treated endothelial cells via NADPH oxidase-dependent IkappaB kinase/NF-kappaB pathway. clematichinenoside 0-18 intercellular adhesion molecule 1 Homo sapiens 39-45 25463279-0 2015 Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-alpha-treated endothelial cells via NADPH oxidase-dependent IkappaB kinase/NF-kappaB pathway. clematichinenoside 0-18 tumor necrosis factor Homo sapiens 60-69 25463279-0 2015 Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-alpha-treated endothelial cells via NADPH oxidase-dependent IkappaB kinase/NF-kappaB pathway. clematichinenoside 0-18 nuclear factor kappa B subunit 1 Homo sapiens 139-148 22994412-0 2013 Anti-arthritic effects of clematichinenoside (AR-6) on PI3K/Akt signaling pathway and TNF-alpha associated with collagen-induced arthritis. clematichinenoside 26-44 AKT serine/threonine kinase 1 Rattus norvegicus 60-63 34149365-0 2021 Retraction: Clematichinenoside Serves as a Neuroprotective Agent Against Ischemic Stroke: The Synergistic Action of ERK1/2 and cPKC Pathways. clematichinenoside 12-30 mitogen-activated protein kinase 3 Homo sapiens 116-122